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Post-partum follow-up of women with gestational diabetes mellitus:
effectiveness, determinants, and barriers
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ABSTRACT
Background: Despite the recommendations for postpartum blood glucose monitoring post ges-
tational diabetes mellitus (GDM); scientific evidence reveals that these recommendations may
not be fully complied to. This study aimed to follow-up women up to 2 years post-delivery with
pregnancies complicated by GDM and healthy controls to assess this fact.
Methods: Women with GDM (n¼ 78) and normal glucose tolerant (n¼ 89) delivered in 2014
were followed up for 2 years. They were informed and enquired via telephone about their blood
glucose screening, physical activity, postpartum complications, and current weight status of
mother and baby.
Results: Women with previous GDM were older and reported higher body weight 2 years post-
delivery. At the 2 year follow-up, n¼ 11 (14.1%) participants had developed diabetes, all with
previous GDM. Both weight at birth (3.8 ± 0.5 kg) and at 2-year (10.7± 2.3 kg) for the babies born
to GDM mothers was significantly higher than the NGT group babies (2.6 ± 0.63 and 7.1± 1.4 kg;
p< .05). Only 27 women regularly opted for T2DM screening via monitoring blood glucose or
HbA1c levels postpartum. The top reason for failed screening included: believing that GDM
would disappear after delivery, and being occupied with the baby.
Conclusions: The high incidence of T2DM in women with previous GDM is an alarming finding.
Given this trend, systematic follow-up programs are needed to reduce obesity and diabetes risk.
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Introduction
Glucose levels are regulated and controlled within set
limits that are physiologically ideal for the body to
perform all functions. For most healthy individuals,
blood glucose levels are tightly controlled between
fasting and fed state [1]. Any derangement in these
levels may lead to development of diabetes in an indi-
vidual. One such form of diabetes seen during preg-
nancy (irrespective of whether the condition prolongs
post-partum or not) is commonly referred to as
Gestational diabetes (GDM). GDM is widespread
around the world, however, the prevalence depends
on the country, region within the country, socio-eco-
nomic status, and dietary habits of an individual, and
the criteria used for diagnosis [2]. One in 250 pregnant
women in the United Kingdom are diabetic, majority
of these cases (87.5%) have GDM [3]. In a recent study
conducted by our group, a GDM prevalence of 17%
for women visiting tertiary care hospitals in Karachi
was reported [4], which is comparable to Western sta-
tistics [5]. However, reports have shown that the com-
plication rates are far greater, plausibly due to poor
glycemic control in our population [6].
Like other forms of diabetes, gestational diabetes
can affect glucose usage by cells which can have
repercussions on maternal, fetal, and neonatal health
and presently GDM can be used as a predictive indica-
tor of morbidity in index pregnancies [7]. Several trials
and studies have shown that it is associated with mul-
tiple fetal and maternal complications, some of which
are shown in schematic Figures 1 and 2 [8]. Even
though serious perinatal complications which are spe-
cifically related to GDM are uncommon, macrosomia is
known to be the predominant complication in cases
of GDM. Moreover, the neonate is also at risk of devel-
oping several problems shown in Figure 3 [9] Q1. In order
to prevent these, early screening and strict blood glu-
cose control is recommended in GDM patients. Apart
from the complications listed above, an additional
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burden on these females is due to the fact that a pre-
vious diagnosis of GDM results in a lifetime risk of
development to Type 2 diabetes mellitus (T2DM) [10].
Though there are no guarantees when they will
develop T2DM postpartum, however, some precaution-
ary measure can reduce the risk of developing it.
These include maintaining high fiber and low fat diet,
regular exercise, and losing excess weight before preg-
nancy and the most important factor regular blood
glucose screening [11,12]. Though, all these facts are
well-known but a vast majority of GDM females do
not follow them. Therefore, we aimed to conduct a fol-
low up study to identify how many GDM positive
females followed the blood glucose screening instruc-
tions and developed any complications during or after
pregnancy at tertiary care hospitals in Karachi,
Pakistan.
Materials and methods
This follow-up study included women with and with-
out GDM with uncomplicated pregnancies delivered in
the year 2014. These women were recruited for the
antenatal care clinics of Abassi Shaheed Hospital,
Karachi. Over 500 pregnant females, less the 20 weeks’
gestation were identified as possible candidates for
the study. Out of the potential subjects, 179 females
(35.8%) consented to participate in the follow-up
study. Eventually, we lost 12 more subjects due to
concurrent pregnancies or failure to respond. The final
sample at the completion of this study was n¼ 167
and this was considered appropriate to achieve a
power of 80% with an alpha of 5% [13]. Subjects with
a pre-pregnancy history of diabetes, hypertension,
conception due to assisted reproductive techniques
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Figure 1. (A–C) Sumarizes the maternal, fetal, and neonatal complications.
2 S. AZIZ ET AL.
and any other maternal–fetal health issues were
excluded from this study. A 75 g oral glucose test was
used to diagnose GDM and normal glucose tolerance
(NGT) in study subjects. The GDM diagnostic criteria
and the desired glucose levels used as a reference in
this study are shown in Table 1. A total of 78 GDM
positive women and 89 healthy controls were followed
up from the time of delivery till 2 year postpartum.
GDM women were managed by either medical nutri-
tion therapy (n¼ 32) or medicine (insulin n¼ 35 and
metformin n¼ 11). Periodic records were made as fol-
lows: (i) antenatal data included pre-pregnancy weight,
body mass index (BMI), family history of diabetes, fast-
ing blood glucose (FBG), HbA1c, fetal growth scans,
and baby birth weight (ii) at delivery data included
maternal and baby birth weight, APGAR score (iii) at
6weeks postpartum data included screening by GTT/
HbA1c, weight status of mother and baby and mater-
nal FBG were recorded. From this point forward all
study subjects received reminders for lifestyle modifi-
cation as well as blood glucose screening via tele-
phone at 6month, 12month, and 24month post-
partum. An independent researcher interviewed all
females and recorded their answers on a prescribed
form. After 2 years these females were examined with
their babies and at that point the weight status and
FBG of the mother and the weight and vaccination
status of the baby were recorded. The WHO growth
chart guidelines were used to assess the age for
weight as follows: (A) weight at birth for boys
3.0–3.7 kg (6.7–8.1 lbs.) and girls 2.9–3.5 kg (6.5–7.8
lbs.) and (B) weight at 24months for boys 11.2–13.1 kg
(24.8–28.9 lbs.) and girls 10.5–12.4 kg (23.3–27.5 lbs.)
[14]. The study was approved by the institutional eth-
ical committee (Table 2) Q10.
Data were analyzed by SPSS version 21 (IBM statis-
tics, Chicago, IL). Quantitative data were presented as
Mean± SD while qualitative data was presented as
absolute number with percentage in parenthesis.
Student t test, Pearson chi-square test/Fisher exact test
were used to compare groups. In all instances p values
< .05 was considered as significant.
Results
The details of the result are shown in Table 1. The
mean age of study subjects with GDM was
28.94 ± 2.84 year while for control was 25.68 ± 3.01 year.
Women with previous GDM had higher body weight
before pregnancy and postpartum compared to the
control group (p< .05). Interestingly, no difference was
observed in both groups in terms of being physically
active. Cesarian section deliveries were common in
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Figure 3. Screening and incidence of T2DM in GDM positive
females.
Figure 2. Periodic fasting blood glucose levels of the study
subjects. The FBG levels at 24–28weeks for NGT and GDM
were77.95± 5.39mg/dl; 96.83± 17.27mg/dl; at 6weeks post-
partum was 81.18± 4.77mg/dl; 117.71 ± 15.05mg/dl and at
2 year postpartum was 84.01 ± 3.64mg/dl and GDM was
97.42 ± 11.70mg/dl, respectively.
Table 1. Diagnostic criteria and glycemic targets for GDM.
International Association of Diabetes and Pregnancy Study Group
(IADPSG) Criteria for GDM diagnosis [1]
GDM is diagnosed when any of the following reading is observed:
Fasting blood glucose (FPG): 92mg/dL (5.1mmol/L)
1-h blood glucose: 180mg/dL (10.0mmol/L)
2-h blood glucose: 153mg/dL (8.5mmol/L)
Recommendation for post-partum screening
Women with a history of GDM should have lifelong screening for the
development of diabetes or pre-diabetes at least every 3 years
Women with a history of GDM found to have pre-diabetes should receive
lifestyle interventions or metformin to prevent diabetes
Diabetes is diagnosed when any of the following is observed
HbA1C: 6.5%
FBG: 126mg/dL (7.0mmol/L)
2-h blood glucose: 200mg/dL (11.1mmol/L) during an OGTT
A random plasma glucose: 200mg/dL (11.1mmol/L)
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GDM group (51%) versus control group (37%), mostly
due to large for gestational age fetus. Both weight at
birth (4.5 ± 0.5 kg) and at 2-year (14.9 ± 2.3) for the
babies born to GDM mothers was significantly higher
than the control group babies (3.6 ± 0.6 and 10.7 ± 1.4;
p< .05). Figure 1(A) shows the blood glucose levels at
28th week of gestation, 6weeks and 2 year post-par-
tum. At all times the FBG for GDM group was higher
than the NGT group (p< .01). Furthermore, in terms of
screening only 27 women with GDM regularly opted
for T2DM screening either by monitoring HbA1c levels
or repeat 75 g glucose tolerance test postpartum.
11 were diagnosed with diabetes at the time of while
three were diagnosed as pre-diabetic follow-up inter-
view. The top reason given for not following screening
instruction was that GDM would disappear after deliv-
ery, testing will falsely diagnose them as T2DM and
being occupied with the baby.
Discussion
Maternal age, higher than normal BMI, high parity,
previous history of gestational diabetes, and family his-
tory of diabetes can pose as risks for developing ges-
tational diabetes [15]. Our results showed that the
group of women with GDM had higher body weight
as opposed to those who did not develop GDM.
Obesity is an established risk factor towards the devel-
opment of both gestational diabetes as well as T2DM
[13]. It affects maternal health and may also have sig-
nificant adverse effects on fetal, neonatal, and long-
term health and well-being [16].
The rate of development of T2DM after a pregnancy
complicated by gestational diabetes ranges from as
low as 2–6% to as high as 70% in studies examining
women from 6weeks to 28 year post-partum [17–20].
Compared to women with a history of normo-glycemic
pregnancies, those with prior GDM have more than
sevenfold increased risk of developing T2DM [21].
Screening for T2DM after pregnancy is, therefore, rec-
ommended every 1–3 years in this risk group.
Intervention strategies can be considered in the case
of early detection, especially in women of childbearing
age resulting in better prognosis [22]. To add to this
burden South Asians are prone to develop diabetes
after GDM at a higher rate and at an earlier stage.
Despite this fact, many women do not follow the
instructions of health care providers and as a result a
golden opportunity of early detection is missed in
most cases.
In the present study, we sent periodic telephonic
reminders to our study participants for blood glucose
screening. Despite all the vigilance, only a limited
number of participants (n¼ 27) opted for the screen-
ing either by 75 g OGTT or by HbA1c level. We report
an alarming incidence 14% (n¼ 11) of T2DM in
females with a past medical history of gestational dia-
betes, and 3.8% (n¼ 3) diagnosed as impaired glucose
tolerant. At the 5-year follow-up study from India
reported the conversion rate to T2DM up to 37% in
women with previous GDM [23]. Furthermore, low
rates of attendance at the 6-week follow-up suggest
that perhaps women with gestational diabetes do not
properly acknowledge the significance of this disorder
as an early warning sign of the susceptibility to
develop T2DM later in life. This behavior identifies the
need for enhancing awareness for both health care
providers as well as women with previous GDM, which
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Table 2. Details of study subjects.
Variable GDM n¼ 78 NGT n¼ 89
Antenatal data
Maternal age (year) 28.94 ± 2.84 25.68 ± 3.01
Maternal weight (<20 weeks gestation) (kg) 69.5 ± 8.22 56.54 ± 5.42
Parity
Primi-parous 63 (80%) 76 (85%)
Multi-parous 15 (20%) 13 (15%)
Intrauterine fetal growth scan
Normal for gestational age 26 (33.3) 62 (69.6)
Large for gestational age 47 (60.0) 17 (19.1)
Small for gestational age 5 (6.4) 10 (11.2)
Delivery data
Normal vaginal delivery 38 (48.7) 56 (62.2)
Cesarian section delivery 40 (51.2) 33 (37.7)
Baby weight at birth (reference range 2.4–4.2 kg) 4.5 ± 0.5 3.6 ± 0.6
Follow-up data
Maternal weight at 6 weeks post-partum (kg) 73.26 ± 6.86 67.23 ± 4.65
Maternal weight at 2 year postpartum (kg) 78.65 ± 12.32 65.22 ± 4.23
Sedentary life style 69 (88.4) 74 (83.1)
30min walk three times a week 09 (11.5) 15 (16.8)
Baby weight at 2 year (reference range 9.5–14.5 kg) 14.9 ± 2.3 10.7 ± 1.4
p< .05.p< .01.
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results in missed opportunities in early identification
and diagnosis.
When we asked the remaining females why they
did not opt for screening despite receiving constant
reminders, the top reasons for failed screening
included believing that GDM would disappear after
delivery, since this is commonly referred to as baby
sugar; they were too occupied with the baby and if
they repeated the test, it will falsely label them as dia-
betic. The lack of compliance for T2DM screening
might be attributed to factors such as fear of insulin
use and long periods of post-partum follow-up [24].
Various other barriers preventing the timely screening
such as “challenges in testing women in the fasting
state, need for repeated testing, screening procedure
being too time consuming, scarcity of test consum-
ables and lack of equipment” are also contributing
factors for the low screening rate [25]. Yet, by utilizing
e-health component in generating awareness and peri-
odic reminders during the course of this study, we
were successful in stimulating 34.6% (n¼ 27) of our
GDM women to get themselves screened. The effect-
iveness of sending periodic reminders in improving
the compliance for testing is also reported by studies
from developed countries such as Canada, Australia,
and USA [26–29].
In addition to the above follow-up findings, we also
collected antenatal and at delivery data of the new-
born. We observed that babies of GDM positive moth-
ers both during intrauterine scans and at delivery had
a higher body weight. This factor was a major con-
tributor to the high rate of cesarean section in this
group. This trend progressed for these babies and at
2 year post-partum; they were at a higher weight for
age percentile when compared with babies born to
NGT females. Previous literature supports a positive
correlation between maternal blood glucose levels,
increased birth weight, and neonatal adiposity [8],
therefore our findings were consistent with them. This
relationship is probably due to fetal hyper-insulinism,
which is secondary to maternal hyperglycemia, and
maternal obesity can act as an additional risk factor to
develop macrosomia.
Like all studies, there are some limitations and
strengths. First, we were unable to recruit a larger
number of subjects, and second only limited number
of recruits was complaint with screening protocol.
Third, screening bias is a concern when there is a
potential for more health-conscious women to regu-
larly see a physician, thus increasing their chance of
receiving a medical diagnosis. Yet, there are various
strengths as to being a follow-up study in Pakistan
where there is scarcity of follow up-based research.
Moreover, based on the Pakistani population, the
homogeneity of this study advantageously reduces
potential sources of unmeasured confounding. Future
research will result in greater advances in this field.
This study also allows for recommendations to be
formed and implemented, which will work towards
better pregnancy care. Further, we have established
that there is a dire need to spread awareness of the
complications of GDM, encouraging mothers to follow-
up on their glucose levels even after pregnancy.
Additionally, physical activity should be advised to
reduce the burden of disease in GDM patients.
Conclusions
Lack of awareness for follow-up screening in GDM
positive women is high in our region. The incidence of
developing T2DM in 14% women with previous GDM
in a short-term follow up study is an alarming finding.
Given this trend, systematic follow-up programs and
awareness of both physicians and pregnant women
are needed to reduce obesity and diabetes risk.
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